These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33517832)

  • 1. Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases.
    Odoom JK; Obodai E; Boateng G; Diamenu S; Attiku K; Avevor P; Duker E; Boahene B; Eshun M; Gberbie E; Opare JKL
    Hum Vaccin Immunother; 2021 Jul; 17(7):2117-2124. PubMed ID: 33517832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
    Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
    Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epidemiological analysis of Acute Flaccid Paralysis (AFP) surveillance in Kenya, 2016 to 2018.
    Tesfaye B; Sowe A; Kisangau N; Ogange J; Ntoburi S; Nekar I; Muitherero C; Camara Y; Gathenji C; Langat D; Sergon K; Limo H; Nzunza R; Kiptoon S; Kareko D; Onuekwusi I
    BMC Infect Dis; 2020 Aug; 20(1):611. PubMed ID: 32811467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to back-to-back outbreaks of circulating vaccine-derived poliovirus type 2 in two nomadic pastoralist settlements in Oti Region, Ghana-2019.
    Ameme DK; Yeboah YO; Odoom JK; Djokoto SK; Akyereko E; Mamudu A; Diwura M; Opare W; Avevor P; Diamenu S; Ohene SA; Kenu E; Asiedu-Bekoe F
    Arch Public Health; 2023 Jan; 81(1):1. PubMed ID: 36600260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping a polio outbreak in the midst of war: Lessons from Syria.
    Mbaeyi C; Moran T; Wadood Z; Ather F; Sykes E; Nikulin J; Al Safadi M; Stehling-Ariza T; Zomahoun L; Ismaili A; Abourshaid N; Asghar H; Korukluoglu G; Duizer E; Ehrhardt D; Burns CC; Sharaf M
    Vaccine; 2021 Jun; 39(28):3717-3723. PubMed ID: 34053791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Morais A; Morais J; Felix M; Neto Z; Madaleno V; Umar AS; Panda N; Lemma F; Chivale JAL; Cavalcante DG; Davlantes E; Ghiselli M; Espinosa C; Whiteman A; Iber J; Henderson E; Bullard K; Jorba J; Burns CC; Diop O; Gumede N; Seakamela L; Howard W; Frawley A
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A48-A57. PubMed ID: 36803869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.
    Al-Qassimi MA; Al Amad M; Al-Dar A; Al Sakaf E; Al Hadad A; Raja'a YA
    BMC Infect Dis; 2024 Mar; 24(1):321. PubMed ID: 38491425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.
    Chen P; Liu Y; Wang H; Liu G; Lin X; Zhang W; Ji F; Xu Q; Tao Z; Xu A
    Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32444474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
    Macklin GR; Goel AK; Mach O; Tallis G; Ahmed JA; O'Reilly KM; Grassly NC; Diop OM
    Vaccine; 2023 Apr; 41 Suppl 1():A19-A24. PubMed ID: 36008232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.
    Etsano A; Damisa E; Shuaib F; Nganda GW; Enemaku O; Usman S; Adeniji A; Jorba J; Iber J; Ohuabunwo C; Nnadi C; Wiesen E
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):770-3. PubMed ID: 27490081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field investigation and response to a vaccine-derived poliovirus pre-tOPV switch in Southwest Nigeria, October 2015.
    Fatiregun A; Famiyesin E; Bawa S; Ogunbodede N
    Pan Afr Med J; 2020; 37():6. PubMed ID: 32983324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021.
    Yang H; Qi Q; Zhang Y; Wen N; Cao L; Liu Y; Fan C; Yan D; Zhu X; Hao L; Zhu S; Ma Q; Liu J; Ma C; Nan L; Chen Y; Ma X; Chen N; Deng K; Shao G; Ding X; An Z; Rodewald LE; Li X; Wang D; Zhu H; Wang H; Feng Z; Xu W; Zhou J; Yin Z;
    JAMA Netw Open; 2023 Jan; 6(1):e2249710. PubMed ID: 36602797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes in polioviruses identified by environmental surveillance in Guangzhou, 2009-2021.
    Chen M; Zhang Y; Zhang W; Huang S; Zhu S; Li C; Guo X; Zeng H; Fang L; Ke B; Li H; Yoshida H; Xu W; Ke C; Deng X; Zheng H
    J Med Virol; 2023 Mar; 95(3):e28668. PubMed ID: 36905116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute flaccid paralysis surveillance performance from 2011 to 2020 in Jonglei State, South Sudan: progress and challenges encountered.
    Jil JM; Tegegne AA; Maleghemi S; Berta KK; Birru TG; Kilo OTD
    Pan Afr Med J; 2022; 42(Suppl 1):11. PubMed ID: 36158927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the immunity status of children with non-polio acute flaccid paralysis who had not received any doses of oral polio vaccine in the South-South region, Nigeria 2011-2014.
    Bassey BE; Vaz RG; Braka F; Komakech W; Maleghemi ST; Akpan GU; Okocha-Ejeko A
    Public Health; 2016 Oct; 139():148-153. PubMed ID: 27302057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress toward poliomyelitis eradication--Nigeria, January 2013-September 2014.
    Etsano A; Gunnala R; Shuaib F; Damisa E; Mkanda P; Banda R; Korir C; Enemaku O; Corkum M; Usman S; Davis LB; Nganda Gw; Burns CC; Mahoney F; Vertefeuille JF;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(46):1059-63. PubMed ID: 25412063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.